Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical
Sanofi and Regeneron are teaming up on new medicines together. Sanofi is paying billions now and later if these drugs work out.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.